7 citations
,
March 2024 in “Skin Research and Technology” This study identified miR-200c-3p as influencing key genes in the EGFR resistance pathway, suggesting its potential theranostic role in addressing issues related to this pathway.
2 citations
,
June 2023 in “Skin Research and Technology” This study reviewed 39 studies with 3204 patients to identify characteristic trichoscopic findings in alopecia areata, highlighting yellow and black dots, broken, short vellus, and tapering hairs as key indicators. It found no single diagnostic trichoscopic finding but observed trichoscopy's utility in monitoring treatment response.
7 citations
,
October 2022 in “Expert opinion on emerging drugs” This review reports on new and effective drug developments for treating severe alopecia areata, including oral baricitinib, but emphasizes that no treatment guarantees permanent remission or works for all patients, with high recurrence rates after stopping medication.
40 citations
,
August 2022 in “Frontiers in immunology” This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.
290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
1 citations
,
October 2020 in “International Journal of Research in Dermatology” This study found that short vellus hair and yellow dots are common dermoscopic findings in alopecia areata, with variations indicating disease activity or remission.
88 citations
,
August 2019 in “Frontiers in immunology” This review discusses the role of tyrosine kinase signaling pathways in autoimmune and inflammatory skin diseases and reports no new clinical results, highlighting ongoing research into small-molecule tyrosine kinase inhibitors as potential treatments.
15 citations
,
April 2019 in “Journal of Cellular Biochemistry” This study identified specific miRNAs that are potentially linked to severe active alopecia areata, suggesting they could be targets for future treatment development.
1 citations
,
March 2019 in “Actas Dermo-Sifiliográficas” This review discusses the adverse effects on hair associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for comprehensive documentation of these effects.
14 citations
,
March 2017 in “Genes and immunity” Certain microRNAs may help treat alopecia areata by targeting immune pathways.
70 citations
,
April 2016 in “Experimental Dermatology” In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.
65 citations
,
December 2015 in “Experimental dermatology” This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.
44 citations
,
September 2015 in “Annals of Oncology” This study reported that targeted anticancer therapies are associated with an increased risk of alopecia compared to placebo, although the risk was lower compared to chemotherapy.
12 citations
,
May 2015 in “Molecular Medicine Reports” This study demonstrated that troxerutin may protect human dermal papilla cells from H2O2-induced damage and suggests potential in treating alopecia by inhibiting ROS-mediated cellular damage.
103 citations
,
November 2014 in “Journal of Cell Biology” This study found that overexpression of miR-214 in keratinocytes inhibits hair follicle development and cycling by targeting β-catenin in the Wnt signaling pathway.
22 citations
,
March 2012 in “Molecular Medicine Reports” This study found that DHT treatment led to reduced cell growth, increased cell death, cell cycle arrest, ROS production, and senescence in normal human dermal papilla cells, potentially mediated by altered miRNA expression.
29 citations
,
October 2011 in “British Journal of Dermatology” This study found that four microRNAs, which were significantly upregulated in balding hair follicle papilla cells, could play a role in the development of male pattern baldness.
12 citations
,
February 2010 in “Journal of The American Academy of Dermatology” This article discusses the use of cetuximab for recurrent squamous cell skin cancer in palliative care, noting good responses but frequent cutaneous side effects; it presents no new findings.
21 citations
,
October 2009 in “Molecular Biology Reports” 33 citations
,
June 2009 in “Journal of Cutaneous Pathology” This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.
